Prescribing information

 

Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1

A Worldwide Antihistamine-Refractory chronic urticaria (CU) patient Evaluation (AWARE) is a global prospective, non-interventional study of chronic urticaria in the real-world setting.2

Dr Sinisa Savic, Consultant Immunologist and Clinician Scientist at Leeds Teaching Hospitals NHS Trust, gives an overview of findings from the global AWARE study and how they can help shape the future of clinical practice in CSU.

Video from a symposium event at the British Association of Dermatologists (BAD) Annual Meeting (delivered virtually).

 

 

Click here for Xolair® (omalizumab) prescribing information

*Post hoc analysis of phase 3 studies,3 omalizumab 300 mg significantly improved total DLQI scores  vs placebo: ASTERIA I: mean decrease from baseline to week 12 of −10.3 vs −6.1 (p<0.0001); ASTERIA II: −10.2 vs −6.1 (p=0.0004); GLACIAL: −9.7 vs −5.1 (p<0.0001).

BAD, British Association of Dermatologists; CSU, chronic spontaneous urticaria.

References

  1. Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
  2. Maurer M, et al. Clin Exp Allergy. 2017;47:684–692.
  3. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.
Rate this content: 
No votes yet
UK | June 2022 | 221825
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]